Node way out.

M S Vaphiades; H Brown; S M Whitcup

doi:10.1016/s0039-6257(00)00133-8

Home/Archive/PubMed

PubMed · 10946083

Node way out.

M S Vaphiades·H Brown·S M Whitcup

View original source ↗Export metadata ↓

Abstract

A 47-year-old woman without a history of melanoma experienced visual hallucinations, abnormal visual field, and an ERG suggestive of melanoma-associated retinopathy (MAR). A lymph node biopsy showed malignant melanoma. Appropriate evaluation, management, and treatment of MAR is discussed.

Explore related subjects

Antibodies, Neoplasm Diagnosis, Differential Electroretinography Female Hallucinations Humans Melanoma Middle Aged Night Blindness Paraneoplastic Syndromes Retinal Diseases Skin Neoplasms Visual Acuity Visual Fields Case Reports Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M S Vaphiades, H Brown, S M Whitcup. Node way out.. https://doi.org/10.1016/s0039-6257(00)00133-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Fc gamma receptors and cross-presentation in dendritic cells.

Explore the source record for details and available documents.

Antibodies, Neoplasm↗

PubMed2002

Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides.

Anti-p53 antibodies have been detected in the sera of patients with various types of cancers. In this report, we describe the development of a new ELISA aimed at detecting anti-p53 antibodies using two peptides belonging to immunodominant epitopes of the p53 N-terminal region. We first tested the reactivity of the sera by an indirect ELISA using the peptides as a capture system. Then, the specificity of the reaction was confirmed by an inhibition assay. Two systems of peptide presentation, phage display and the streptavidin/biotin system, were evaluated. Using a panel of sera from cancer patients, both systems were found to be equally reliable, demonstrating that both peptide-based ELISAs can be used for the specific detection of anti-p53 antibodies. The presence of anti-p53 antibodies was associated with p53 alteration whether it be mutation or accumulation.

Antibodies, Neoplasm↗

PubMed2002

Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

Uncontrolled expansion of donor-derived Epstein-Barr virus (EBV)-infected B cells has become a significant problem in recipients of allogeneic hematopoietic stem cell transplantations. Major risk factors for the early development of posttransplantation lymphoproliferative disease include the use of unrelated or HLA-mismatched related donors, selective T-cell depletion of donor marrow, and the use of antithymocyte globulin or monoclonal anti-T-cell antibodies for the prophylaxis and treatment of acute graft-versus-host disease. Over the past few years, the administration of in vitro-generated EBV-specific cytotoxic T cells or anti-B-cell monoclonal antibodies has provided effective options for the prophylaxis or treatment of posttransplantation lymphoproliferative disease. Advances in quantitative polymerase chain reaction-based assays allow both the precise measurement of EBV load in peripheral blood samples and the identification of high-risk patients for early initiation of therapy. A major remaining challenge is to assess the significance of an elevated EBV load posttransplantation and to determine the indications for preemptive treatment.

Antibodies, Neoplasm↗